Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Shwetha Lakshmipathi"'
Autor:
David McDermott, Virginia Seery, Rupal Bhatt, Adrian Wells, Mamta Gupta, Brian Halbert, David Einstein, Emanuelle Andrianopoulos, Kenneth Onimus, Courtney Herman, Shwetha Lakshmipathi, Arvind Natarajan, Anand Veerapathran
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/ac294b04595448f389f6a445c691e5f3
Autor:
Adrian Wells, Arvind Natarajan, Anand Veerapathran, Shwetha Lakshmipathi, Courtney Herman, Joe Wypych, Viktoria Gontcharova, Nermin Gerges, Kenneth Onimus
Publikováno v:
Journal for ImmunoTherapy of Cancer. 9:A110-A110
BackgroundLifileucel (LN-144) and LN-145, adoptive cell therapies using autologous tumor-infiltrating lymphocytes (TIL), have demonstrated encouraging efficacy with acceptable safety in a variety of tumor types.1–4 The lifileucel Gen 2 clinical man
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f1a58a9d933f5d375697407128d120cc
https://doi.org/10.1136/jitc-2021-sitc2021.101
https://doi.org/10.1136/jitc-2021-sitc2021.101
Autor:
Brian Halbert, David Einstein, David McDermott, Emanuelle Andrianopoulos, Mamta Gupta, Virginia Seery, Kenneth Onimus, Courtney Herman, Adrian Wells, Shwetha Lakshmipathi, Arvind Natarajan, Anand Veerapathran, Rupal Bhatt
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundPatients with RCC may achieve remission with immune-checkpoint inhibitors (ICI); however, most patients will progress. Adoptive cell therapy with autologous TIL allows for expansion of T-cells from tumor tissue leading to a polyclonal T-cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b0f7e44e3bde4ea1e72ec0df4f22c31
https://doi.org/10.1136/jitc-2021-sitc2021.176
https://doi.org/10.1136/jitc-2021-sitc2021.176